The nasal spray reshaping depression treatment does not work like any antidepressant most people have encountered. Spravato, the brand name for esketamine, targets the glutamate system rather than the serotonin pathways that SSRIs and SNRIs have relied on for decades. Approved by the FDA in January 2025 as the first and only stand-alone monotherapy for treatment-resistant depression, Spravato blocks NMDA receptors and triggers a rapid surge in glutamate, activating neuroplasticity and synaptogenesis in ways that can produce measurable improvement within 24 hours. For the roughly 30 percent of depression patients who never respond adequately to conventional medications, this represents a fundamentally different biological approach to a disease that has long been reduced to a “chemical imbalance” in serotonin. But Spravato is not the only nasal spray exploring an unconventional pathway.
An investigational compound called PH10, developed by Vistagen Therapeutics under the brand name Itruvone, works through an even more unusual mechanism. It binds to chemosensory neurons inside the nasal passages and sends signals directly to the limbic amygdala without ever entering systemic circulation. It does not act on serotonin, GABA, or even glutamate. If the clinical data hold up, it could represent an entirely new category of psychiatric treatment. This article breaks down how the glutamate pathway differs from traditional antidepressants, what the clinical trial numbers actually show for Spravato’s monotherapy approval, the practical realities of cost and access, and where the experimental pherine-based approach fits into the future of depression care, particularly for older adults and those managing cognitive decline alongside mood disorders.
Table of Contents
- How Does This Nasal Spray for Depression Work by a Different Pathway Than Traditional Antidepressants?
- What the Monotherapy Clinical Trial Data Actually Show
- The Safety Restrictions and What They Mean in Practice
- What Spravato Costs and How to Navigate Insurance Coverage
- Dissociation, Misuse Potential, and Long-Term Unknowns
- PH10 and the Pherine Pathway — A Completely Novel Approach
- What These New Pathways Mean for the Future of Depression and Brain Health
- Conclusion
- Frequently Asked Questions
How Does This Nasal Spray for Depression Work by a Different Pathway Than Traditional Antidepressants?
Every SSRI, SNRI, and tricyclic antidepressant on the market operates on the same basic premise: increase the availability of monoamine neurotransmitters, primarily serotonin and norepinephrine, in the synaptic cleft. This approach has dominated psychiatric medicine since the late 1980s. Spravato breaks from that model entirely. As research from Washington University and Johns Hopkins Medicine has documented, esketamine blocks NMDA receptors on glutamate neurons, the brain’s most abundant excitatory neurotransmitter system. This blockade causes a compensatory surge of glutamate that activates AMPA receptors and stimulates the mTORC1 signaling pathway, which governs protein synthesis and the formation of new synaptic connections. The practical difference is speed.
SSRIs typically require four to six weeks to produce noticeable effects because they depend on gradual downstream neurochemical changes. Spravato’s direct stimulation of synaptogenesis and brain-derived neurotrophic factor production can generate measurable symptom relief within hours to days. For someone in acute depressive crisis, or for an older adult whose cognitive reserve is already compromised by depression’s neurotoxic effects, that timeline matters enormously. To put it in concrete terms: a patient who has tried two or three SSRIs over the course of a year without adequate response is clinically classified as having treatment-resistant depression. Before January 2025, that patient could only receive Spravato as an add-on to yet another oral antidepressant. Now, Spravato can be prescribed on its own, eliminating the requirement for a concurrent medication that, by definition, was not working well enough in the first place.
What the Monotherapy Clinical Trial Data Actually Show
The Phase 4 trial that led to Spravato’s expanded FDA approval provides the clearest picture of what patients can realistically expect. At the four-week mark, 22.5 percent of patients receiving esketamine achieved full remission, compared with 7.6 percent on placebo. That is roughly a threefold difference, but it also means more than three-quarters of patients on esketamine did not reach remission within that timeframe. Significant improvement in depressive symptoms was observed within 24 hours of the first dose, which is striking, but early response does not always predict sustained remission. These numbers deserve honest context. A 22.5 percent remission rate is meaningful in a population that has already failed multiple treatments, but it is not a cure rate.
Treatment-resistant depression is notoriously difficult to move, and any intervention that triples the remission rate over placebo in this group represents real clinical progress. However, if you or a family member are considering Spravato, the expectation should be calibrated: it works dramatically well for some patients and modestly or not at all for others. There is currently no reliable biomarker to predict who will respond. For older adults, particularly those with co-occurring mild cognitive impairment or early dementia, the data are thinner. The pivotal trials enrolled adults broadly but did not specifically power for geriatric subgroups. Clinicians treating elderly patients with treatment-resistant depression must weigh Spravato’s potential cognitive benefits from enhanced neuroplasticity against the sedation and dissociation risks that may be amplified in aging brains.
The Safety Restrictions and What They Mean in Practice
Spravato cannot be picked up at a pharmacy and used at home. The FDA requires it to be administered exclusively through a Risk Evaluation and Mitigation Strategy program, which means every dose must be given in a certified healthcare setting where the patient can be monitored for at least two hours afterward. This restriction exists because of documented risks of sedation, dissociation, respiratory depression, and potential for misuse, risks inherited from esketamine’s parent compound, ketamine, which has a long history as both an anesthetic and a recreational drug. For a patient managing depression alongside early-stage dementia, these logistics can be significant. Twice-weekly clinic visits during the induction phase require reliable transportation, a caregiver who can accompany the patient and drive them home, and a healthcare facility within reasonable distance that carries REMS certification.
Rural patients and those without strong support networks face real barriers. The dissociative effects, which can include perceptual disturbances and a sense of detachment from reality, may also be particularly distressing for someone already experiencing cognitive confusion, though clinical reports vary on this point. The monitoring requirement is not arbitrary caution. During clinical trials, some patients experienced clinically significant blood pressure elevations, and the dissociative episodes, while typically short-lived, can be intense. For older adults on blood pressure medications or those with cardiovascular risk factors, the prescribing clinician must evaluate whether the expected benefit justifies these acute physiological stresses.
What Spravato Costs and How to Navigate Insurance Coverage
The financial reality of Spravato treatment is substantial. Individual sessions typically cost between $590 and $885 before insurance, and the induction phase requires twice-weekly sessions for the first four weeks. That translates to roughly $4,700 to $7,080 for the first month alone, before transitioning to weekly or biweekly maintenance dosing. Most commercial insurance plans cover Spravato for treatment-resistant depression after prior authorization, but the documentation requirements can be burdensome, and some plans impose step therapy requirements that add months to the approval process. Medicare Part B generally covers Spravato when administered in a physician’s office, which is the most common setting, but patients are still responsible for copays and coinsurance that can be significant without supplemental coverage.
Johnson & Johnson offers a patient assistance program and a copay savings card for commercially insured patients, which can reduce out-of-pocket costs considerably. The tradeoff worth acknowledging is that the total cost of Spravato treatment over a year, even with insurance, often exceeds the annual cost of generic SSRIs by an order of magnitude. For some patients with treatment-resistant depression, that expenditure buys a qualitatively different outcome. For others, the financial strain may not be justified by the degree of improvement they experience. Compared with IV ketamine infusions, which are rarely covered by insurance and can run $400 to $800 per session entirely out of pocket, Spravato’s insurance pathway represents a meaningful advantage. But compared with a $4 monthly generic sertraline prescription, the cost differential is stark and worth discussing openly with a prescriber before committing to the treatment course.
Dissociation, Misuse Potential, and Long-Term Unknowns
The dissociative effects of Spravato are not a side effect in the traditional sense. They are a pharmacological consequence of NMDA receptor blockade, and while some researchers have speculated that the dissociative experience itself may contribute to therapeutic benefit, the evidence for that claim is not settled. What is clear is that roughly 60 to 70 percent of patients experience some degree of dissociation during or after administration, ranging from mild perceptual changes to more pronounced episodes of derealization. These effects typically resolve within two hours, which is why the monitoring period exists. The misuse potential is a legitimate clinical concern. Ketamine and its derivatives have established abuse liability, and while the REMS program is designed to prevent diversion, no distribution system is perfectly sealed.
For patients with a personal or family history of substance use disorders, the decision to use Spravato requires careful risk-benefit discussion. This is especially relevant in dementia care contexts, where the patient may not be the primary decision-maker and caregivers must understand both the potential benefits and the reasons for the controlled distribution framework. Long-term safety data remain limited. Spravato was first approved in 2019, which provides roughly six years of post-marketing experience, but robust long-term outcome data for patients on maintenance dosing over many years are still accumulating. The effects of chronic NMDA receptor modulation on an aging brain, particularly one already undergoing neurodegenerative changes, are not well characterized. This is not a reason to avoid the treatment, but it is a reason to maintain ongoing monitoring and honest conversations with the treatment team about what is known and what is not.
PH10 and the Pherine Pathway — A Completely Novel Approach
While Spravato represents a new pathway relative to SSRIs, an even more unconventional approach is in development. PH10, known as Itruvone, is a synthetic pherine developed by Vistagen Therapeutics that works through nasal chemosensory neurons rather than any traditional neurotransmitter system. When sprayed into the nasal passages, PH10 binds to receptors on specialized chemosensory cells that send signals directly to the limbic amygdala, the brain region central to emotional regulation and stress response. Critically, the compound does not enter systemic circulation, which means it does not produce the sedation, dissociation, or blood pressure changes associated with Spravato.
PH10 received FDA Fast Track designation in late 2022 for major depressive disorder, and the first patients were dosed in a U.S. Phase 1 trial in January 2023, following a positive Phase 2A study conducted in Mexico. Preclinical work has confirmed that PH10 does not directly activate GABA-A receptors, distinguishing it mechanistically from benzodiazepines, and its lack of systemic absorption could theoretically make it far more practical for elderly patients who are sensitive to drug-drug interactions and central nervous system side effects. Phase 2B development is still pending, so this remains an investigational compound without proven efficacy in large trials. But the concept of modulating mood through peripheral chemosensory signaling rather than flooding the brain with a psychoactive substance is genuinely novel.
What These New Pathways Mean for the Future of Depression and Brain Health
The broader significance of both Spravato and PH10 extends beyond depression treatment itself. The glutamate system plays a central role in learning, memory, and synaptic plasticity, processes that deteriorate in Alzheimer’s disease and other dementias. The fact that Spravato promotes BDNF production and synaptogenesis raises the question of whether treating depression through this pathway might simultaneously provide some neuroprotective benefit, though no clinical trial has been designed to test that hypothesis directly. For the millions of older adults living at the intersection of depression and cognitive decline, this is more than an academic question.
If PH10’s mechanism proves effective in later-stage trials, it could open an entirely new therapeutic category, one defined not by which neurotransmitter it modulates but by the peripheral sensory route it exploits. The history of psychiatry has been dominated by drugs that alter brain chemistry systemically, with all the side effects that entails. A future in which mood regulation can be achieved through targeted nasal chemosensory signaling, without sedation, without dissociation, without systemic drug exposure, would represent a genuine paradigm shift. That future is not guaranteed, but the science is moving in a direction that deserves close attention from patients, caregivers, and clinicians alike.
Conclusion
Depression treatment is no longer a one-pathway story. Spravato’s FDA-approved glutamate-based mechanism offers a real alternative for the substantial number of patients who do not respond to serotonin-targeted medications, with clinical data showing threefold remission rates over placebo and symptom improvement within 24 hours. Its January 2025 monotherapy approval removes the requirement for a concurrent oral antidepressant, simplifying treatment for those who have already proven that conventional approaches are insufficient. At the same time, its cost, safety monitoring requirements, and dissociative effects mean it is not a casual prescription, particularly for older adults managing both depression and cognitive concerns.
For caregivers and families navigating treatment-resistant depression in someone with dementia or mild cognitive impairment, these developments warrant a direct conversation with a psychiatrist familiar with both the glutamate pathway and the specific vulnerabilities of the aging brain. Ask about REMS-certified facilities in your area, insurance coverage specifics, and whether the patient’s cardiovascular and cognitive profile is compatible with esketamine’s known risks. And keep PH10 on your radar. It is still investigational, but its mechanism, acting through nasal chemosensory neurons without systemic absorption, could eventually offer a depression treatment with a side-effect profile far better suited to the elderly population that needs it most.
Frequently Asked Questions
Is Spravato the same as ketamine?
Not exactly. Spravato is esketamine, the S-enantiomer of ketamine. It targets the same NMDA receptors but is a specific, FDA-approved formulation delivered as a nasal spray under medical supervision. Generic ketamine, often given as an IV infusion in off-label clinics, is a different product with a different regulatory and insurance landscape.
Can Spravato be used at home?
No. Due to risks of sedation, dissociation, and misuse, Spravato must be administered in a REMS-certified healthcare facility. Patients are monitored for at least two hours after each dose and cannot drive for the rest of the day.
How quickly does Spravato work compared to SSRIs?
Clinical trial data show significant improvement in depressive symptoms within 24 hours of the first Spravato dose, due to its direct stimulation of glutamate-driven neuroplasticity. SSRIs typically require four to six weeks to produce noticeable effects.
Is PH10 (Itruvone) available for prescription?
No. PH10 is still investigational. It completed a Phase 1 trial in the U.S. in 2023 and received FDA Fast Track designation in late 2022, but Phase 2B trials are still pending. It is not available outside of clinical research settings.
Does Spravato interact with dementia medications like donepezil or memantine?
This is a question for the prescribing psychiatrist, as formal interaction studies in dementia populations are limited. Notably, memantine is also an NMDA receptor antagonist, which raises theoretical questions about combined use that should be discussed with a specialist.
How much does a full course of Spravato treatment cost?
Individual sessions run $590 to $885 before insurance. The induction phase requires twice-weekly visits for four weeks, potentially totaling $4,700 to $7,080 for the first month. Maintenance dosing frequency varies. Insurance coverage, including Medicare Part B, is available but often requires prior authorization.
